Pfizer shot remains more than 91% effective after six months
The Peninsula
Pfizer Inc.’s Covid-19 vaccine remained highly effective after six months, according to new long-term results that the company said could be used to seek an expansion of its regulatory status.
Follow-up data from a final-stage trial of 46,307 people showed the vaccine was 91.3% effective in preventing symptomatic cases starting one week after the second dose through as long as six months. In the U.S. alone, the efficacy rate was 92.6%, according to a report Thursday by Pfizer and its partner BioNTech SE. At the same time, the companies provided some of the first data on how their vaccine might handle the immune-evading B.1.351 variant that arose in South Africa.More Related News